Podcast
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
The 3 “Knows” of Effective Scientific Communication
Summary
In this episode, Tom Caravela is joined by guest Linda Traylor who discusses the 3 "knows" of scientific communication for Medical Science Liaisons (MSLs). She shares the framework of scientific communication and its impact on the value and expectations of medical affairs. Self-awareness and audience analysis are emphasized to enhance engagement. The episode highlights common mistakes in audience interaction and data contextualization, offering professional development tips. It also covers storytelling techniques and strategies for effective meetings with Key Opinion Leaders (KOLs). The episode concludes with a book recommendation, acknowledgment of guest expertise, and additional resources.
Key Points
- Understanding and adapting to the evolving landscape of scientific communication, including the use of AI tools and digital platforms, is crucial for medical affairs teams.
- MSLs should focus on the three essential aspects of effective communication: knowing themselves, knowing their audience, and knowing their subject, to maximize engagements with healthcare professionals.
- Building self-awareness through tools like personality assessments, aligning communication styles with the audience to eliminate distractions, and contextualizing data within the patient, HCP, and product journeys are key strategies for successful scientific exchanges.
scientific communication, Medical Science Liaisons, audience analysis, storytelling techniques, Key Opinion Leaders
Related Topics
You May Also Like
MSL Talk: Tom Caravela, Conor McGladrigan, Kevin Peterson
Podcast
MSL Talk: Tom Caravela
How to Start Presenting Like a Pro
Article
S.F. Oosting, J. Barriuso, A. Bottomley, M. Galotti, B. Gyawali, B. Kiesewetter, N.J. Latino, F. Martinelli, M. Pe, G. Pentheroudakis, F. Roitberg, H. Vachon, E.G.E. de Vries, M. Piccart, N.I. Cherny
Methodological and reporting standards for quality-of-life data eligible for European Society for Medical Oncology-Magnitude of Clinical Benefit Scale
Article
Dylan V Neel, David S Shulman, Clement Ma, Florence Bourgeois, Steven G DuBois
Sponsorship of oncology clinical trials in the United States according to age of eligibility
Article
Michael Z. Liao, Dan Lu, Matts Kågedal, Dale Miles, Divya Samineni, Stephanie N. Liu, Chunze Li
Model-Informed Therapeutic Dose Optimization Strategies for Antibody-Drug Conjugates in Oncology: What Can We Learn From US Food and Drug Administration-Approved Antibody-Drug Conjugates?
Article
Karen Geary